DMARDs effectively relieve rheumatoid and psoriatic arthritis pain

Intensive treatments using DMARDs for rheumatoid and psoriatic arthritis significantly reduce pain, according to new research. This finding supports shifting pain management focus away from opioids. Studies analyzed data from multiple trials, showing more patients achieved mild pain levels with intensive DMARD treatment compared to control groups. Significant pain score reductions were also observed. Researchers concluded that optimizing disease activity with DMARDs is crucial for pain control in RA and PsA, aligning with existing guidelines. Further research explores the impact of metabolic syndrome on pain.